What does it take to move a disease from having “no approved treatment” to having “a new therapeutic option”? … Sometimes it’s years of trial data building toward a single moment. In other cases, it involves extending an established therapeutic approach into a genetically defined population. Recently, three FDA approvals for cancer and rare neurodegenerative diseases capture three different paths to that point: biomarker-selected treatment intensification, the first FDA-approved treatment for a specific rare-disease manifestation, and gene replacement for a severe pediatric neurodegenerative disease.
Here’s what these three approvals mean for the specialty therapy landscape.
| Company | Drug Name | Active Ingredient | Disease / Indication | FDA Approval Date |
|---|---|---|---|---|
| Eli Lilly | Inluriyo + Verzenio (combination) | Imlunestrant + abemaciclib | ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer | September 18, 2026 |
| IntraBio | AQNEURSA | Levacetylleucine | Ataxia-telangiectasia (A-T) | September 18, 2026 |
| Ultragenyx | Fayuvi | Rebisufligene etisparvovec | Sanfilippo syndrome type A / MPS IIIA | September 17, 2026 |
Eli Lilly’s Inluriyo–Verzenio Combination Approval Extends Treatment Options After Progression in ESR1-Mutated Breast Cancer
The Food and Drugs Administration (FDA) has recently approved the use of imlunestrant (Inluriyo) and abemaciclib (Verzenio), a two-drug combination therapy for adult patients diagnosed with ER-positive, HER2-negative, ESR1-mutated locally advanced/metastatic breast cancer. The combination treatment will be offered to patients who have received prior endocrine therapy but have progressed after receiving such treatment.
The approval was granted based on patients’ mutations being detected by an FDA-authorized test. It is a subsequent therapy pathway to follow when endocrine treatments fail rather than a first-line alternative. Both drugs aim at two different pathways relevant to ER-positive breast cancer. Specifically, imlunestrant blocks and degrades the oestrogen receptor, while abemaciclib inhibits CDK4/6 and restricts tumour-cell proliferation.
Based on an exploratory analysis of 159 patients with ESR1-mutated tumors from the Phase 3 EMBER-3 trial, median progression-free survival for the group receiving combination therapy was 11.1 months versus 5.5 months for those treated with Inluriyo monotherapy.
Also Read: Pharma Snapshot – Targeted Therapies Take the Center Stage in FDA Approval
IntraBio’s AQNEURSA Becomes the First Approved Treatment for Ataxia-Telangiectasia
AQNEURSA (levacetylleucine) has received FDA approval for the treatment of adult and pediatric patients with ataxia weighing at least 15 kg with ataxia-telangiectasia. It is the first FDA-approved treatment for ataxia associated with ataxia-telangiectasia (A-T). A-T is a rare, inherited neurodegenerative disease caused by mutations in the ATM gene that affects approximately 1 in 40,000 people worldwide. Before this approval, treatment options for its neurological symptoms were limited.
The support for AQNEURSA was based on a randomized, double-blind, placebo-controlled, two-period crossover trial involving 73 patients aged four years and older. Patients received the treatment AQNEURSA and placebo for 12 weeks in each period. The efficacy was assessed using the Functional Scale for Assessment and Rating of Ataxia (fSARA).
Patients had better fSARA scores while receiving AQNEURSA than while receiving placebo. This marks AQNEURSA’s second approved indication by the USFDA, after its 2024 approval for Niemann-Pick disease type C. IntraBio’s amino acid-based platform is positioned as a reusable mechanism to potentially treat related neurodegenerative conditions.
Ultragenyx’s Fayuvi Delivers the First Disease-Modifying Therapy for Sanfilippo Syndrome Type A
Fayuvi (rebisufligene etisparvovec-hopf) is a single-dose intravenous gene therapy based on AAV9 vectors, and has been approved for the treatment of neurological manifestations of MPS IIIA (Sanfilippo syndrome type A) in pediatric patients with intact neurocognitive development. MPS IIIA is a rare neurodegenerative disease affecting an estimated 3,000 to 5,000 patients in developed countries. Fayuvi replaces a functional copy of the SGSH gene that may allow cells to produce the missing enzyme sulfamidase, which is needed to break down a sugar called heparan sulfate in our bodies. The estimated wholesale acquisition cost of this therapy is $3.95 million, reflecting the list price before discounts, rebates, or potential treatment outcomes-based reimbursement policies.
Approval followed accelerated review of data showing meaningful cognitive and functional benefit versus natural history and comes a year after the FDA rejected the therapy over manufacturing issues, now resolved across Ultragenyx’s Massachusetts facility and a third-party partner. It is Ultragenyx’s second FDA approval within a month, arriving as the broader rare disease gene therapy category regains regulatory momentum after a period of heightened scrutiny.
IeB Perspective
Reaching New Patients Takes More Than Just an Approval …
Across these three approvals, the innovation is not only biological. It’s also about which patients can now be identified and treated: younger patients, ultra-rare populations, or those who progress on first-line treatment. Whether through weight-based pediatric dosing, a one-time gene therapy replacing years of symptom management, or a validated sequencing strategy in oncology, each approval extends precision medicine further into populations that were previously underserved by existing options.
For specialty therapies, translating that access into practice depends on infrastructure as much as evidence, from gene therapy administration capacity to payer alignment on ultra-high-cost one-time treatments to diagnostic pathways that can actually identify these rare patient populations early.
Fill out the form below or email us at contact@iebrain.com to talk to our industry experts and discuss strategies and impactful business approaches.
